CD163 and Familial prostate cancer: Considering only the presence of macrophages in the enrolled prostate cancer lesions, a significant increase in M2 macrophages (CD163-positive cells) was observed in PCM+ as compared to PCM− (PCM− 102.7 ± 13.7; PCM+ 163.3 ± 21.2; p = 0.008) (Figure 4C).